Pharmacokinetics of metoprolol during pregnancy and lactation

Rachel J. Ryu, Sara Eyal, Thomas R. Easterling, Steve N. Caritis, Raman Venkataraman, Gary Hankins, Erik Rytting, Kenneth Thummel, Edward J. Kelly, Linda Risler, Brian Phillips, Matthew T. Honaker, Danny D. Shen, Mary F. Hebert

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    The objective of this study was to evaluate the steady-state pharmacokinetics of metoprolol during pregnancy and lactation. Serial plasma, urine, and breast milk concentrations of metoprolol and its metabolite, α-hydroxymetoprolol, were measured over 1 dosing interval in women treated with metoprolol (25-750 mg/day) during early pregnancy (n = 4), mid-pregnancy (n = 14), and late pregnancy (n = 15), as well as postpartum (n = 9) with (n = 4) and without (n = 5) lactation. Subjects were genotyped for CYP2D6 loss-of-function allelic variants. Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P

    Original languageEnglish (US)
    Pages (from-to)581-589
    Number of pages9
    JournalJournal of Clinical Pharmacology
    Volume56
    Issue number5
    DOIs
    StatePublished - May 1 2016

    Fingerprint

    Metoprolol
    Lactation
    Pharmacokinetics
    Pregnancy
    Cytochrome P-450 CYP2D6
    Loss of Heterozygosity
    Human Milk
    Postpartum Period
    Urine

    Keywords

    • breast milk
    • CYP2D6
    • hypertension
    • metoprolol
    • pharmacokinetics
    • pregnancy

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology

    Cite this

    Ryu, R. J., Eyal, S., Easterling, T. R., Caritis, S. N., Venkataraman, R., Hankins, G., ... Hebert, M. F. (2016). Pharmacokinetics of metoprolol during pregnancy and lactation. Journal of Clinical Pharmacology, 56(5), 581-589. https://doi.org/10.1002/jcph.631

    Pharmacokinetics of metoprolol during pregnancy and lactation. / Ryu, Rachel J.; Eyal, Sara; Easterling, Thomas R.; Caritis, Steve N.; Venkataraman, Raman; Hankins, Gary; Rytting, Erik; Thummel, Kenneth; Kelly, Edward J.; Risler, Linda; Phillips, Brian; Honaker, Matthew T.; Shen, Danny D.; Hebert, Mary F.

    In: Journal of Clinical Pharmacology, Vol. 56, No. 5, 01.05.2016, p. 581-589.

    Research output: Contribution to journalArticle

    Ryu, RJ, Eyal, S, Easterling, TR, Caritis, SN, Venkataraman, R, Hankins, G, Rytting, E, Thummel, K, Kelly, EJ, Risler, L, Phillips, B, Honaker, MT, Shen, DD & Hebert, MF 2016, 'Pharmacokinetics of metoprolol during pregnancy and lactation', Journal of Clinical Pharmacology, vol. 56, no. 5, pp. 581-589. https://doi.org/10.1002/jcph.631
    Ryu RJ, Eyal S, Easterling TR, Caritis SN, Venkataraman R, Hankins G et al. Pharmacokinetics of metoprolol during pregnancy and lactation. Journal of Clinical Pharmacology. 2016 May 1;56(5):581-589. https://doi.org/10.1002/jcph.631
    Ryu, Rachel J. ; Eyal, Sara ; Easterling, Thomas R. ; Caritis, Steve N. ; Venkataraman, Raman ; Hankins, Gary ; Rytting, Erik ; Thummel, Kenneth ; Kelly, Edward J. ; Risler, Linda ; Phillips, Brian ; Honaker, Matthew T. ; Shen, Danny D. ; Hebert, Mary F. / Pharmacokinetics of metoprolol during pregnancy and lactation. In: Journal of Clinical Pharmacology. 2016 ; Vol. 56, No. 5. pp. 581-589.
    @article{c859552442484ffc872da52695b67de5,
    title = "Pharmacokinetics of metoprolol during pregnancy and lactation",
    abstract = "The objective of this study was to evaluate the steady-state pharmacokinetics of metoprolol during pregnancy and lactation. Serial plasma, urine, and breast milk concentrations of metoprolol and its metabolite, α-hydroxymetoprolol, were measured over 1 dosing interval in women treated with metoprolol (25-750 mg/day) during early pregnancy (n = 4), mid-pregnancy (n = 14), and late pregnancy (n = 15), as well as postpartum (n = 9) with (n = 4) and without (n = 5) lactation. Subjects were genotyped for CYP2D6 loss-of-function allelic variants. Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P",
    keywords = "breast milk, CYP2D6, hypertension, metoprolol, pharmacokinetics, pregnancy",
    author = "Ryu, {Rachel J.} and Sara Eyal and Easterling, {Thomas R.} and Caritis, {Steve N.} and Raman Venkataraman and Gary Hankins and Erik Rytting and Kenneth Thummel and Kelly, {Edward J.} and Linda Risler and Brian Phillips and Honaker, {Matthew T.} and Shen, {Danny D.} and Hebert, {Mary F.}",
    year = "2016",
    month = "5",
    day = "1",
    doi = "10.1002/jcph.631",
    language = "English (US)",
    volume = "56",
    pages = "581--589",
    journal = "Journal of Clinical Pharmacology",
    issn = "0091-2700",
    publisher = "SAGE Publications Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Pharmacokinetics of metoprolol during pregnancy and lactation

    AU - Ryu, Rachel J.

    AU - Eyal, Sara

    AU - Easterling, Thomas R.

    AU - Caritis, Steve N.

    AU - Venkataraman, Raman

    AU - Hankins, Gary

    AU - Rytting, Erik

    AU - Thummel, Kenneth

    AU - Kelly, Edward J.

    AU - Risler, Linda

    AU - Phillips, Brian

    AU - Honaker, Matthew T.

    AU - Shen, Danny D.

    AU - Hebert, Mary F.

    PY - 2016/5/1

    Y1 - 2016/5/1

    N2 - The objective of this study was to evaluate the steady-state pharmacokinetics of metoprolol during pregnancy and lactation. Serial plasma, urine, and breast milk concentrations of metoprolol and its metabolite, α-hydroxymetoprolol, were measured over 1 dosing interval in women treated with metoprolol (25-750 mg/day) during early pregnancy (n = 4), mid-pregnancy (n = 14), and late pregnancy (n = 15), as well as postpartum (n = 9) with (n = 4) and without (n = 5) lactation. Subjects were genotyped for CYP2D6 loss-of-function allelic variants. Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P

    AB - The objective of this study was to evaluate the steady-state pharmacokinetics of metoprolol during pregnancy and lactation. Serial plasma, urine, and breast milk concentrations of metoprolol and its metabolite, α-hydroxymetoprolol, were measured over 1 dosing interval in women treated with metoprolol (25-750 mg/day) during early pregnancy (n = 4), mid-pregnancy (n = 14), and late pregnancy (n = 15), as well as postpartum (n = 9) with (n = 4) and without (n = 5) lactation. Subjects were genotyped for CYP2D6 loss-of-function allelic variants. Using paired analysis, mean metoprolol apparent oral clearance was significantly higher in mid-pregnancy (361 ± 223 L/h, n = 5, P

    KW - breast milk

    KW - CYP2D6

    KW - hypertension

    KW - metoprolol

    KW - pharmacokinetics

    KW - pregnancy

    UR - http://www.scopus.com/inward/record.url?scp=84964199962&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84964199962&partnerID=8YFLogxK

    U2 - 10.1002/jcph.631

    DO - 10.1002/jcph.631

    M3 - Article

    VL - 56

    SP - 581

    EP - 589

    JO - Journal of Clinical Pharmacology

    JF - Journal of Clinical Pharmacology

    SN - 0091-2700

    IS - 5

    ER -